1 BTC
=
- USD
Omeros Corporation
As of May 30, 2026 at 24:05 UTC
Chart
About Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Market Statistics
Trading Metrics
How to Buy OMER
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy OMER
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesSagimet Biosciences appointed Dr. Andreas Grauer as Chief Medical Officer effective April 20, 2026, replacing retiring Dr. Eduardo Martins who will serve as external scientific advisor. Grauer brings over two decades of biopharmaceutical leadership experience from roles at Omeros, Federation Bio, Corcept Therapeutics, and Amgen. He received an inducement stock option grant valued at $1.34 million as part of his employment compensation.
Omeros stock surged nearly 76% after receiving FDA approval for Yartemlea, a treatment for TA-TMA (hematopoietic stem cell transplant-associated thrombotic microangiopathy), a potentially fatal complication from stem cell transplants. This is the first and only FDA-approved treatment for this indication. The company plans to launch the drug in January 2026 and has established billing codes and patient support programs.
The complement 3 glomerulopathy market is projected to grow at a 37.2% CAGR from 2025-2034, driven by increasing disease awareness, advances in complement pathway research, and emerging targeted therapies targeting novel complement mechanisms.
